These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19913209)

  • 1. Safety profile of IBD therapeutics: infectious risks.
    Afif W; Loftus EV
    Gastroenterol Clin North Am; 2009 Dec; 38(4):691-709. PubMed ID: 19913209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of IBD therapeutics: infectious risks.
    Afif W; Loftus EV
    Med Clin North Am; 2010 Jan; 94(1):115-33. PubMed ID: 19944801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of infections with biological agents.
    Kopylov U; Afif W
    Gastroenterol Clin North Am; 2014 Sep; 43(3):509-24. PubMed ID: 25110256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary.
    Veereman-Wauters G; de Ridder L; Veres G; Kolacek S; Fell J; Malmborg P; Koletzko S; Dias JA; Misak Z; Rahier JF; Escher JC;
    J Pediatr Gastroenterol Nutr; 2012 Jun; 54(6):830-7. PubMed ID: 22584748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for opportunistic infections in patients with inflammatory bowel disease.
    Toruner M; Loftus EV; Harmsen WS; Zinsmeister AR; Orenstein R; Sandborn WJ; Colombel JF; Egan LJ
    Gastroenterology; 2008 Apr; 134(4):929-36. PubMed ID: 18294633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease.
    Epple HJ
    Dig Dis; 2009; 27(4):555-9. PubMed ID: 19897974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectious and malignant complications of TNF inhibitor therapy in IBD.
    Targownik LE; Bernstein CN
    Am J Gastroenterol; 2013 Dec; 108(12):1835-42, quiz 1843. PubMed ID: 24042192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
    Strangfeld A; Listing J
    Best Pract Res Clin Rheumatol; 2006 Dec; 20(6):1181-95. PubMed ID: 17127203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects of biologics used for treating IBD.
    Stallmach A; Hagel S; Bruns T
    Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):167-82. PubMed ID: 20227030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunistic infections due to inflammatory bowel disease therapy.
    Dave M; Purohit T; Razonable R; Loftus EV
    Inflamm Bowel Dis; 2014 Jan; 20(1):196-212. PubMed ID: 24051931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
    Winthrop KL
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with biologic therapies and the risk of cancer in patients with IBD.
    Biancone L; Calabrese E; Petruzziello C; Pallone F
    Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
    Kwon JH; Farrell RJ
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
    Van Assche G; Lewis JD; Lichtenstein GR; Loftus EV; Ouyang Q; Panes J; Siegel CA; Sandborn WJ; Travis SP; Colombel JF
    Am J Gastroenterol; 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PubMed ID: 21844919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Infectious risks of immunomodulating therapies in rheumatology].
    Van Delden C
    Rev Med Suisse; 2006 Mar; 2(57):738-40, 743-5. PubMed ID: 16604876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First attack of inflammatory bowel disease and infectious colitis. A clinical, histological and microbiological study with special reference to early diagnosis.
    Schumacher G
    Scand J Gastroenterol Suppl; 1993; 198():1-24. PubMed ID: 8115839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory therapy for inflammatory bowel disease.
    Kusugami K; Ina K; Ando T; Hibi K; Nishio Y; Goto H
    J Gastroenterol; 2004 Dec; 39(12):1129-37. PubMed ID: 15622475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
    Chan EP; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.